Extent of Lymphadenectomy and Outcome for Patients With Stage I Nonsmall Cell Lung Cancer
Extent of Lymphadenectomy and Outcome for Patients With Stage I Nonsmall Cell Lung Cancer
复制标题
DOI：
10.1002/cncr.23985
复制
发表时间：
2009-02-15
期刊：
影响因子：
6.2
通讯作者：
DeCamp, Malcolm M.
中科院分区：
文献类型：
--
作者：
Varlotto, John M.;Recht, Abram;DeCamp, Malcolm M.
背景：淋巴结切除术（LA）是否会影响I期非小细胞肺癌（NSCLC）患者的总生存率（OS）或无病生存率（DFS），以及应该恢复的最佳淋巴结数量尚不确定。方法：从1992年到2002年，24,273例诊断为I期NSCLC的患者被纳入监测、流行病学和最终结果数据库，并接受了明确的外科手术。中位随访时间为35个月。结果：对于整个人群，LA与5年OS率从41.6%增加到58.4%相关(P
BACKGROUND: It is uncertain whether lymphadenectomy (LA) affects overall survival (OS) or disease-free survival (DFS) rates for patients with stage I nonsmall cell lung cancer (NSCLC), as is the optimal number of lymph nodes that should be recovered. METHODS: There were 24,273 patients with stage I NSCLC diagnosed from 1992 to 2002 who were included in the Surveillance, Epidemiology, and End Results database and who underwent a definitive surgical procedure. Median follow-up was 35 months. RESULTS: For the entire population, having LA was associated with an increase in the 5-year OS rate from 41.6% to 58.4% (P